A detailed history of Hall Capital Management CO Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Hall Capital Management CO Inc holds 6,115 shares of BMY stock, worth $244,538. This represents 0.16% of its overall portfolio holdings.

Number of Shares
6,115
Previous 5,865 4.26%
Holding current value
$244,538
Previous $300,000 10.33%
% of portfolio
0.16%
Previous 0.18%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$47.98 - $54.4 $11,995 - $13,600
250 Added 4.26%
6,115 $331,000
Q2 2022

Jul 19, 2022

SELL
$72.62 - $79.98 $29,048 - $31,992
-400 Reduced 6.38%
5,865 $452,000
Q4 2020

Mar 02, 2021

SELL
$57.74 - $65.43 $6,062 - $6,870
-105 Reduced 1.65%
6,265 $389,000
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $2,010 - $2,227
-35 Reduced 0.55%
6,370 $384,000
Q1 2020

Apr 29, 2020

SELL
$46.4 - $67.43 $9,280 - $13,486
-200 Reduced 3.03%
6,405 $357,000
Q4 2019

Feb 04, 2020

BUY
$49.21 - $64.19 $15,009 - $19,577
305 Added 4.84%
6,605 $424,000
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $59,121 - $65,375
-1,325 Reduced 17.38%
6,300 $286,000
Q1 2019

May 06, 2019

SELL
$45.12 - $53.8 $15,792 - $18,830
-350 Reduced 4.39%
7,625 $364,000
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $9,020 - $11,697
-185 Reduced 2.27%
7,975 $415,000
Q3 2018

Nov 05, 2018

SELL
$55.19 - $62.25 $26,822 - $30,253
-486 Reduced 5.62%
8,160 $507,000
Q2 2018

Aug 14, 2018

SELL
$50.53 - $62.98 $174,985 - $218,099
-3,463 Reduced 28.6%
8,646 $478,000
Q4 2017

Feb 02, 2018

SELL
$59.94 - $65.35 $29,970 - $32,674
-500 Reduced 3.97%
12,109 $742,000
Q3 2017

Oct 19, 2017

SELL
$55.23 - $63.74 $127,581 - $147,239
-2,310 Reduced 15.48%
12,609 $804,000
Q2 2017

Aug 14, 2017

BUY
N/A
14,919
14,919 $831,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $85B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Hall Capital Management CO Inc Portfolio

Follow Hall Capital Management CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hall Capital Management CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Hall Capital Management CO Inc with notifications on news.